Trial Profile
A Retrospective, multicentre study to assess the risk of sinusoidal obstruction syndrome (SOS) associated with Gemtuzumab Ozogamicin treatment prior to Allogenic stem cell transplantation in patients with Acute myeloid leukemia
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Jan 2017
Price :
$35
*
At a glance
- Drugs Gemtuzumab ozogamicin (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 30 Jan 2017 New trial record
- 16 Jan 2017 Results published in the Bone Marrow Transplantation